港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

抗疫概念

922.671

+26.1432.92%

漲家數：11

跌家數：5

平家數：2

市盈率：- -

高：932.797

開：893.740

低：891.998

收：896.528

資料載入中...

總覽新聞資訊

比亞迪和青山重申在智利建廠的意向此前智利稱項目已取消

廣東天普生化醫藥股份有限公司申請III類會議

券商聚焦醫藥領域持倉、調研多管齊下覓先機

中國駐智利大使館：比亞迪和青山未公司停止投資願與當地政府對話

石藥集團1類新藥SYH2046獲FDA批准開展臨牀試驗

復星醫藥(02196)附屬菌濟健康獲美國 FDA 藥品臨牀試驗批准

阿里吳泳銘再提創業，將採用“飽和式投入”打法

石藥集團(01093)：SYH2046片獲美國臨牀試驗批准

石藥集團：SYH2046片獲美國臨牀試驗批准

即時零售大戰前傳：互聯網健康的十年“三國殺”

华尔街见闻

石藥集團(01093)5月9日註銷2545萬股已回購股份

爭奪水光針200億市場華熙生物接連獲批2款合規產品四環醫藥、樂普醫療加入混戰

“太平洋醫藥”君實生物公司點評：拓益收入同比增長 46%，關注 DKK1 胃腸道腫瘤早期數據

復星醫藥子公司獲美國FDA批准開展AGA治療臨牀試驗

山東新華製藥股份(00719)收到依帕司他片《藥品補充申請批准通知書》

復星醫藥(600196.SH)控股子公司獲美國FDA藥品臨牀試驗批准

京東健康05月09日主力淨流出825.6萬元散戶資金買入

中國中藥05月09日獲主力加倉60.1萬元

國藥控股05月09日獲主力加倉257.3萬元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1515/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"抗疫概念","latestPrice":922.6707,"timestamp":1747037290222,"preClose":896.528,"halted":0,"volume":639468156,"delay":0,"changeRate":0.02916,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":26.1427,"latestTime":"05-12 16:00:00","open":893.73975,"high":932.79736,"low":891.99774,"amount":5930868565.5,"amplitude":0.045508,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1747099800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1747013400000,1747022400000],[1747026000000,1747036800000]],"pbRate":1.585523,"peRate":21.198848,"turnoverRate":0.008452,"increases":11,"decrements":6,"flats":1,"marketCap":634840009216,"floatMarketCap":524045002368},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":932.79736,"amplitude":0.045508,"preClose":896.528,"low":891.99774,"pbRate":"1.585523","latestPrice":922.6707,"volume":639468156,"delay":0,"open":893.73975,"prevYearClose":787.97723,"prevWeekClose":896.528,"prevMonthClose":903.998,"prevQuarterClose":870.015,"fiveDayClose":921.416,"twentyDayClose":756.168,"sixtyDayClose":879.539,"secType":"PLATE","market":"HK","turnoverRate":0.008452,"peRate":21.198848,"marketCap":634840009216,"floatMarketCap":524045002368,"timestamp":1747037290222,"nameCN":"抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":11,"down":5,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2534283418","title":"比亞迪和青山重申在智利建廠的意向 此前智利稱項目已取消","url":"https://stock-news.laohu8.com/highlight/detail?id=2534283418","media":"商业周刊","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534283418?lang=zh_tw&edition=fundamental","pubTime":"2025-05-10 10:04","pubTimestamp":1746842640,"startTime":"0","endTime":"0","summary":"比亚迪和青山控股重申在智利建设锂加工厂的意向，这似乎与智利政府关于项目已被取消的说法形成反差。此前，智利当地报纸Diario Financiero报道称，比亚迪与青山已决定不再推进把碳酸锂加工为电池正极材料的项目。就比亚迪而言，这家电动汽车巨头未能与智利当局就项目条款达成协议。负责管理智利锂资源的政府机构Corfo5月7日声明称，比亚迪已于今年1月撤回了工厂选址。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-05-10/doc-inevzyrc7759163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1522","002594","BK0188","LU2148510915.USD","LU0588546209.SGD","LU0254981946.USD","81211","BK0183","LU0561508036.HKD","BK1515","LU1997245177.USD","LU0359202008.SGD","LU2097828714.EUR","LU0314109678.HKD","HYDD.SI","BYDDY","LU2289578879.USD","LU2506951792.HKD","LU1719994722.HKD","00285","BK1607","LU0823414551.USD","BK1504","LU0516422440.USD","EVS.SI","LU0175139822.USD","LU1251922891.USD","01211","LU0588545490.SGD","LU1880383440.USD","LU2399975544.HKD","BK1594","LU2580892862.HKD","BK1580","BK1119","BK0264","LU1303224171.USD","LU0856984785.SGD","LU0164865239.USD","LU0320764599.SGD","BK0072","LU0708995583.HKD","LU1188198961.HKD","LU0540923850.HKD","LU0634319403.HKD","LU0823426308.USD","IE00BD6J9T35.USD","LU1868837565.USD","BK0014","LU2294711713.HKD"],"gpt_icon":1},{"id":"2534462146","title":"廣東天普生化醫藥股份有限公司申請III類會議","url":"https://stock-news.laohu8.com/highlight/detail?id=2534462146","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534462146?lang=zh_tw&edition=fundamental","pubTime":"2025-05-10 07:22","pubTimestamp":1746832978,"startTime":"0","endTime":"0","summary":"广东天普生化医药股份有限公司，成立于1993年，位于广州市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，广东天普生化医药股份有限公司共对外投资了4家企业，参与招投标项目758次，知识产权方面有商标信息34条，专利信息102条，此外企业还拥有行政许可119个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/10072250281720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1515","BK4134","09939","159938","III","BK1161","BK1574"],"gpt_icon":0},{"id":"2534458269","title":"券商聚焦醫藥領域 持倉、調研多管齊下覓先機","url":"https://stock-news.laohu8.com/highlight/detail?id=2534458269","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534458269?lang=zh_tw&edition=fundamental","pubTime":"2025-05-10 00:34","pubTimestamp":1746808440,"startTime":"0","endTime":"0","summary":"在当前市场环境下，券商正通过重仓买入医药板块相关标的、加大对医药行业的研究分析力度以及扩大在医药领域的投资规模等举措，全方位、多层次地深化与医药板块的关联。在持仓变化方面，一季度券商对于医药板块的持仓调整动作频繁，新进持有10只个股，增持3只个股，减持11只个股。今年以来，券商积极调研医药板块相关公司，紧密关注该领域发展动态。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-05-10/doc-inevyxcn3939697.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-05-10/doc-inevyxcn3939697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1161","09939","159938","BK1574"],"gpt_icon":0},{"id":"2534332874","title":"中國駐智利大使館：比亞迪和青山未公司停止投資 願與當地政府對話","url":"https://stock-news.laohu8.com/highlight/detail?id=2534332874","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534332874?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 22:17","pubTimestamp":1746800240,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["SG9999002828.SGD","LU0979878070.USD","EVS.SI","LU0211977185.USD","LU0269904917.USD","BK1515","HYDD.SI","LU1961090484.USD","LU0823038988.USD","LU0540923850.HKD","LU1813983027.USD","01211","LU0683595622.HKD","LU0175139822.USD","LU1328277881.USD","LU0588546209.SGD","LU0244354667.USD","LU0633140560.USD","LU0823414551.USD","LU1880383440.USD","LU2039709279.SGD","00285","LU1781817850.SGD","BK1594","LU0348767384.USD","SG9999014674.SGD","LU1861214812.USD","LU1794554557.SGD","LU2289578879.USD","LU0531971595.HKD","LU0039217434.USD","LU0819123356.HKD","BYDDY","LU0561508036.HKD","LU1580142542.USD","LU1868837565.USD","IE00BD6J9T35.USD","81211","LU0348827113.USD","LU2148510915.USD","LU1064131003.USD","LU1720050803.USD","LU0327786744.USD","LU2663582299.SGD","LU0531970944.HKD","BK0169","LU1303224171.USD","002594","LU0359202008.SGD","LU0516422366.SGD"],"gpt_icon":0},{"id":"2534100774","title":"石藥集團1類新藥SYH2046獲FDA批准開展臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2534100774","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534100774?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 19:01","pubTimestamp":1746788515,"startTime":"0","endTime":"0","summary":"5月9日，石药集团发布公告，宣布其开发的化药1类新药SYH2046片已获得美国食品药品监督管理局批准，可以在美国开展临床试验。该产品也已于2025年4月获得中国国家药品监督管理局的批准，允许在中国进行临床试验。SYH2046片是一款具有完全自主知识产权的全新结构first-in-class小分子药物，主要适应症为急性心肌梗死后心力衰竭。目前，公司已在国内外提交多项该产品的专利申请。文章来源：财中社石药集团1类新药SYH2046获FDA批准开展临床试验","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509191055a6d902d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509191055a6d902d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0501845795.SGD","BK1141","LU1226287792.SGD","LU0072913022.USD","BK1583","IE0008368742.USD","BK1191","LU1226288253.USD","IE00BZ08YT58.USD","LU1226287875.USD","LU0067412154.USD","LU1152091754.HKD","LU0326950275.SGD","LU1951186391.HKD","LU1993786604.SGD","LU1960683339.HKD","LU1152091168.USD","LU1226287529.USD","01093","IE00BZ08YS42.EUR","LU1226288170.HKD","IE00BZ08YR35.GBP","03347","LU0880133367.SGD","IE00B5MMRT66.SGD","LU0140636845.USD","LU1807302812.USD","BK1576","SG9999004220.SGD","BK1521","IE00B031HY20.USD","LU1008478684.HKD","IE0008369823.USD","BK1515","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2534104693","title":"復星醫藥(02196)附屬菌濟健康獲美國 FDA 藥品臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2534104693","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534104693?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 18:48","pubTimestamp":1746787704,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，该公司控股子公司上海菌济健康科技有限公司(以下简称“菌济健康”)收到美国 FDA(即美国食品药品监督管理局)关于同意 LBP-ShC4 开展临床试验的批准。菌济健康拟于条件具备后开展 LBP-ShC4 的 I 期临床试验。LBP-ShC4 为集团自主研发的活体生物治疗产品，拟用于治疗雄激素脱发(AGA)。截至 2025 年 4 月，集团现阶段针对 LBP-ShC4 的累计研发投入约为人民币 0.17 亿元(未经审计)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","03347","BK0175","BK0060","600196","BK0096","BK0239","BK0187","BK0183","BK0196","BK0028","BK1593","02196","BK1515","BK1583","BK0012","BK1576","BK1141","BK1191"],"gpt_icon":0},{"id":"2534894824","title":"阿里吳泳銘再提創業，將採用“飽和式投入”打法","url":"https://stock-news.laohu8.com/highlight/detail?id=2534894824","media":"虎嗅APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534894824?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 18:47","pubTimestamp":1746787620,"startTime":"0","endTime":"0","summary":"与此同时，吴泳铭提出“饱和式投入”打法。虎嗅独家获悉，吴泳铭所提及的饱和式投入除了围绕AI、云等核心业务的硬件与资源投入外，还包括了对于既有绩效机制、组织流程等维度的改革。吴泳铭内部信的背景是“510阿里日”。今年阿里日和以往的差异是，阿里高层希望集团内的精神面貌有所变化。接下来集团将以饱和式投入的打法，聚焦于几大核心战役。阿里的基因里没有“守成”，只有“创造”。阿里人，回归初心，重新创业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2656090065&idx=3&sn=6940aef2d3b7d4f1f0e3bad5f9d5ba01&chksm=67ed2897f36cada55889f319cef10b1dec5b2f57d6dce9f4f61b2df4a0bcbfe5f7ba9f17516b&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK4535","ALBmain","BK4554","BK4585","BABA","BK1571","LU1769817096.USD","LU0979878070.USD","LU1823568750.SGD","LU1242518857.USD","BK1501","LU1152091168.USD","LU1152091754.HKD","00241","LU1046421795.USD","LU1769817179.HKD","BK1142","LU0348816934.USD","LU0880133367.SGD","BK4533","IE00B0JY6N72.USD","LU0821914370.USD","LU1048588211.SGD","LU1242518931.SGD","IE00BFMHRM44.USD","LU0047713382.USD","09988","LU1282648689.USD","LU0328353924.USD","BK1591","BK4122","LU0918141705.HKD","BK4220","BK1189","BK1247","BK4575","BK4581","LU1235294995.USD","LU0310800965.SGD","BK1515","BK4565","LU0052756011.USD","LU0918141887.USD","BK4505","161022","LU0651947912.USD","LU1688375341.USD","BK1589","BK4503"],"gpt_icon":1},{"id":"2534106973","title":"石藥集團(01093)：SYH2046片獲美國臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2534106973","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534106973?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 18:31","pubTimestamp":1746786691,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的化药1类新药SYH2046片(该产品)已获得美国食品药品监督管理局批准，可以在美国开展临床试验。该产品是一款具有完全自主知识产权的全新结构first-in-class小分子药物，本次获批的临床试验适应症为急性心肌梗死后心力衰竭。临床前研究表明，该产品可显着改善疾病动物模型的心脏功能并降低心脏不良重构，且具有较高的安全性。目前，本集团已在国内外提交该产品的多项专利申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0008368742.USD","BK1576","03347","IE00BZ08YT58.USD","LU1152091168.USD","LU1226287792.SGD","01093","LU0140636845.USD","LU1951186391.HKD","LU1807302812.USD","IE00B5MMRT66.SGD","LU1226287529.USD","BK1515","SG9999004220.SGD","BK1141","LU1226288170.HKD","LU1993786604.SGD","IE00BZ08YS42.EUR","LU0072913022.USD","LU1960683339.HKD","BK1583","LU0880133367.SGD","LU1008478684.HKD","IE00BZ08YR35.GBP","LU1152091754.HKD","BK1191","BK1521","LU1226287875.USD","IE00B543WZ88.USD","LU1226288253.USD","LU0326950275.SGD","IE00B031HY20.USD","IE0008369823.USD","LU0067412154.USD","LU0501845795.SGD"],"gpt_icon":0},{"id":"2534310591","title":"石藥集團：SYH2046片獲美國臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2534310591","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534310591?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 18:29","pubTimestamp":1746786595,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1226287529.USD","LU1807302812.USD","01093","BK1515","IE00B543WZ88.USD","LU0326950275.SGD","BK1576","LU1226287792.SGD","BK1191","LU0140636845.USD","LU1008478684.HKD","LU0067412154.USD","LU1226287875.USD","LU1960683339.HKD","IE0008368742.USD","IE00B031HY20.USD","LU1951186391.HKD","LU0880133367.SGD","LU0072913022.USD","LU1226288253.USD","LU1152091754.HKD","IE0008369823.USD","LU1993786604.SGD","03347","IE00BZ08YS42.EUR","LU1152091168.USD","IE00B5MMRT66.SGD","BK1141","IE00BZ08YR35.GBP","LU0501845795.SGD","LU1226288170.HKD","SG9999004220.SGD","BK1521","IE00BZ08YT58.USD","BK1583"],"gpt_icon":0},{"id":"2534106420","title":"即時零售大戰前傳：互聯網健康的十年“三國殺”","url":"https://stock-news.laohu8.com/highlight/detail?id=2534106420","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534106420?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 18:24","pubTimestamp":1746786254,"startTime":"0","endTime":"0","summary":"互要流量","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/80a4ddb7-699e-49c8-b5bb-3d8b9af64cea.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/80a4ddb7-699e-49c8-b5bb-3d8b9af64cea.png"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3746786","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3746786","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["LU0348827113.USD","LU0231483743.USD","LU1282651121.HKD","METmain","LU0359201885.HKD","LU0819123356.HKD","LU1720051108.HKD","LU2125910500.SGD","06618","LU0463099449.HKD","LU1201861165.SGD","MPNGY","BK1515","HBBD.SI","LU0128525689.USD","03690","LU2257852520.SGD","LU0140636845.USD","LU0531971595.HKD","HMTD.SI","LU1808992512.USD","89988","LU2097828474.EUR","09939","ALBmain","BK4504","LU0181495838.USD","LU0029875118.USD","00241","LU0890818403.SGD","LU2242644610.SGD","89618","BK4579","LU1328277881.USD","LU0871576103.HKD","LU0700851271.USD","BK4524","LU0651946864.USD","LU0315179316.USD","BK1584","86618","LU1046422090.SGD","LU0594300179.USD","LU1675838814.USD","LU1044876610.USD","BK1583"],"gpt_icon":1},{"id":"2534177980","title":"石藥集團(01093)5月9日註銷2545萬股已回購股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2534177980","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534177980?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 17:57","pubTimestamp":1746784654,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)发布公告，于2025年5月9日注销2545万股已回购股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1993786604.SGD","LU1226288253.USD","LU1152091754.HKD","LU1951186391.HKD","LU0880133367.SGD","BK1515","IE00BZ08YS42.EUR","LU0072913022.USD","LU0067412154.USD","LU1807302812.USD","LU1152091168.USD","LU0501845795.SGD","IE00B543WZ88.USD","IE00B031HY20.USD","LU1226287875.USD","LU1226288170.HKD","IE00BZ08YT58.USD","01093","LU0140636845.USD","SG9999004220.SGD","LU0326950275.SGD","LU1226287529.USD","LU1226287792.SGD","LU1960683339.HKD","BK1521","BK1191","IE00BZ08YR35.GBP","IE0008369823.USD","IE0008368742.USD","IE00B5MMRT66.SGD","LU1008478684.HKD"],"gpt_icon":0},{"id":"2534317293","title":"爭奪水光針200億市場 華熙生物接連獲批2款合規產品 四環醫藥、樂普醫療加入混戰","url":"https://stock-news.laohu8.com/highlight/detail?id=2534317293","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534317293?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 17:38","pubTimestamp":1746783517,"startTime":"0","endTime":"0","summary":"近半个月以来，国内已有三款水光针产品获批，且均获得国家药监局三类医疗器械认证。4月末，华熙生物（688363.SH）旗下“润百颜·玻玻”、“润致·缇透”两款水光针产品接连获批。据华熙生物方面所述，润百颜·玻玻为其自主研发的含利多卡因水光针，系国内首个获批“面部肤质改善适应症”的水光产品。润致·缇透则为国内首款以“面部肤质改善”为适应症的合规动能素产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505093400685069.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00460","BK1191","BK1600","BK1593","BK1515"],"gpt_icon":0},{"id":"2534991171","title":"“太平洋醫藥”君實生物公司點評：拓益收入同比增長 46%，關注 DKK1 胃腸道腫瘤早期數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2534991171","media":"新浪财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534991171?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 17:22","pubTimestamp":1746782527,"startTime":"0","endTime":"0","summary":"拓益销售收入保持高增速，公司运营效率显著提升，在手现金 30 亿元。2025 年第一季度公司实现收入 5 亿元， 其中，核心产品特瑞普利单抗于国内市场实现销售收入 4.47 亿元。研发费用 3.51 亿元，同比增加 26.89%；管理费用 0.97 亿元，同比减少 21.32%。拓益国内获批 12 项适应症，国际化布局进展顺利。截止目前，拓益已于国内获批 12 项适应症，10 项适应症纳入国家医保目录，其中 4 项为医保独家适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050917245897544f69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050917245897544f69&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09939","BK1583","01877","BK1515","BK1161"],"gpt_icon":0},{"id":"2534173533","title":"復星醫藥子公司獲美國FDA批准開展AGA治療臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2534173533","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534173533?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 16:37","pubTimestamp":1746779855,"startTime":"0","endTime":"0","summary":"5月9日，复星医药发布公告，控股子公司菌济健康获得美国FDA关于LBP-ShC4开展临床试验的批准。公告指出，目前全球尚无用于治疗雄激素脱发的活体生物治疗产品获批上市。尽管获得临床试验批准，但药品研发存在风险，后续的临床研究仍需获得美国药品审评部门的审批，且临床试验可能因安全性和有效性问题而终止。2025年一季度，复星医药实现收入94.20亿元，归母净利润7.65亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509164519a477e291&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509164519a477e291&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1576","BK1583","02196","BK1593","03347","BK1141","BK1515"],"gpt_icon":0},{"id":"2534917837","title":"山東新華製藥股份(00719)收到依帕司他片《藥品補充申請批准通知書》","url":"https://stock-news.laohu8.com/highlight/detail?id=2534917837","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534917837?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 16:35","pubTimestamp":1746779710,"startTime":"0","endTime":"0","summary":"智通财经APP讯，山东新华制药股份(00719)发布公告，近日，该公司收到国家药品监督管理局核准签发的依帕司他片(以下简称“本品”)《药品补充申请批准通知书》，批准本品上市许可持有人转让补充申请。公告称，2025年5月，新华制药获得药品补充申请批准通知书，依帕司他片通过国家药品监督管理局审批，公司成为本品的上市许可持有人。该产品的上市，有利于丰富公司内分泌系统药物产品线，提升公司综合竞争优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291328.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","00719","BK1191"],"gpt_icon":0},{"id":"2534120770","title":"復星醫藥(600196.SH)控股子公司獲美國FDA藥品臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2534120770","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534120770?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 16:29","pubTimestamp":1746779394,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)公告，公司控股子公司上海菌济健康科技有限公司(简称“菌济健康”)收到美国FDA(即美国食品药品监督管理局)关于同意LBP-ShC4开展临床试验的批准。菌济健康拟于条件具备后开展LBP-ShC4的I期临床试验。据悉，LBP-ShC4为集团(即公司及控股子公司/单位，下同)自主研发的活体生物治疗产品，拟用于治疗雄激素脱发(AGA)。截至本公告日期(2025年5月9日)，于全球范围内尚无用于治疗雄激素脱发(AGA)的活体生物治疗产品(包括单药或联合治疗方案)获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0196","BK1576","BK1593","BK1191","BK0060","BK0175","600196","BK1141","BK0096","BK1583","BK0188","BK1515","BK0028","BK0239","02196","BK0187","BK0183","03347"],"gpt_icon":0},{"id":"2534310654","title":"京東健康05月09日主力淨流出825.6萬元 散戶資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2534310654","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534310654?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 16:15","pubTimestamp":1746778550,"startTime":"0","endTime":"0","summary":"05月09日, 京东健康股价跌3.15%，报收36.85元，成交金额3.1亿元，换手率0.27%，振幅3.55%，量比1.08。京东健康今日主力资金净流出825.6万元，上一交易日主力净流入574.4万元。该股近5个交易日下跌1.62%，主力资金累计净流入6562.3万元；近20日主力资金累计净流入4.7亿元，其中净流入天数为16日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509180327a477fd7a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509180327a477fd7a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1571","BK1142","LU0051755006.USD","06618","86618","BK1589","LU0456827905.SGD","BK1247","BK1583","BK1515","BK1615","BK1591"],"gpt_icon":0},{"id":"2534170191","title":"中國中藥05月09日獲主力加倉60.1萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534170191","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534170191?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 16:15","pubTimestamp":1746778541,"startTime":"0","endTime":"0","summary":"05月09日，中国中药股价收平报2.08元，成交金额2548.3万元，换手率0.24%，振幅1.92%，量比0.61。中国中药今日主力资金净流入60.1万元，上一交易日主力净流入344.2万元。该股近5个交易日上涨2.48%，主力资金累计净流入2709.3万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1.1亿元，其中净流入天数为17日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509175906a6d8eb18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509175906a6d8eb18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1606","BK1191","00570","BK1515"],"gpt_icon":0},{"id":"2534170479","title":"國藥控股05月09日獲主力加倉257.3萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534170479","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534170479?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 16:15","pubTimestamp":1746778538,"startTime":"0","endTime":"0","summary":"05月09日, 国药控股股价涨0.55%，报收18.40元，成交金额7251.9万元，换手率0.29%，振幅1.42%，量比0.54。国药控股今日主力资金净流入257.3万元，上一交易日主力净流入1491.3万元。该股近5个交易日上涨0.22%，主力资金累计净流入5375.7万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2.0亿元，其中净流入天数为15日。该股主力净额占比0.01%，港股市场排名244/2645。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509175750a6d8ea8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509175750a6d8ea8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1500","BK1197","BK1515","LU0640798160.USD","LU1115378108.SGD","01099"],"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":4,"totalSize":349,"code":"91000000","status":"200"}]}}